Compass Pathways (CMPS)

• Market cap: $290M
• 1 day: 4.68%
• 5 days: 15.50%
• 1 month: -9.54%
• 3 months: -10.32%
• 6 months: -50.08%
• Year to date: -24.58%
• 1 year: -63.31%
• 5 years: -89.21%
• 10 years: -89.21%
• Sector: Healthcare
• Industry: Medical Care Facilities

About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Employees: 166

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

13% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $1.26M

4% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 27

3% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 29

1% more funds holding

Funds holding: 129 [Q3] → 130 (+1) [Q4]

2.72% less ownership

Funds ownership: 47.92% [Q3] → 45.21% (-2.72%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

43% less capital invested

Capital invested by funds: $206M [Q3] → $117M (-$89.5M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 251% upside
• Avg. target: $24 656% upside
• High target: $45 1,338% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target	1,338% upside $45	Buy Reiterated	4 Mar 2025
Canaccord Genuity Sumant Kulkarni 7% 1-year accuracy 2 / 29 met price target	379% upside $15	Buy Maintained	28 Feb 2025
Stifel Paul Matteis 6% 1-year accuracy 1 / 16 met price target	251% upside $11	Buy Initiated	27 Feb 2025